ABOUT US

Our Mission

Turnstone Biologics’ mission is to deliver breakthrough viral immunotherapies to improve survival for patients with cancer.

Turnstone Biologics is a privately-held immuno-oncology company based in Ottawa, Ontario. Since 2015, we have raised $50 million in venture capital financing, brought in more than $100 million in non-dilutive funding, and have received numerous biotechnology industry awards, including being named a 2017 Fierce 15 company.

 

Our scientific founders, Drs. John Bell, David Stojdl and Brian Lichty, are world leaders in the oncolytic virus and immunotherapy field. Collectively, they have published more than 200 publications in leading journals, and have spent years engineering and developing viruses to create the next generation of powerful, targeted therapies for cancer patients.

 

Our passionate team of leaders in oncology has decades of experience in biotechnology, academia and pharmaceutical drug development. With comprehensive capabilities in immuno-oncology discovery, basic research, translation, clinical development, manufacturing, and commercialization, we are committed to bringing new medicines to people with cancer to improve their lives.

 

our science

Breakthrough Viral Immunotherapies

Turnstone Biologics is the sole company developing viral immunotherapies that drive benefit through simultaneous generation of targeted immune responses and modulation of the tumor environment.

The Maraba Virus

Turnstone Biologics’ founders screened hundreds of viruses before discovering that Maraba, a single-stranded RNA virus isolated from sand flies around the Maraba region of Brazil, was an optimal platform for cancer therapeutics. Maraba was engineered to MG1 to optimize its safety, selectivity, manufacturability and potency to kill tumor cells, and transgene capacity was added for targeted expression of tumor-associated antigens and immunomodulatory agents.

MG1: The First 2-In-1 Approach

Our engineered oncolytic Maraba virus, known as MG1, is the first therapeutic 2-in-1 approach to combine an oncolytic virus and an antigen-specific cancer vaccine. With its unprecedented dual-mechanism driving robust killer T cell responses and disrupting the tumor microenvironment, MG1 kills cancer cells at metastatic sites throughout the body, and generates a durable immune response resulting in long-term memory to prevent recurrence.

our pipeline

Driven by Science and Innovation

At Turnstone Biologics, we are science-driven: science informs our research, clinical development and approach for patients. We have developed a robust pipeline of new medicines for multiple solid tumors.

Our first program is an engineered Maraba virus (MG1) that expresses the tumor-associated antigen MAGEA3, which is highly expressed on many different types of solid tumors. We are evaluating this therapy in patients with non-small cell lung cancer (NSCLC), breast cancer and esophageal cancer in two clinical trials – alone and in combination with the anti-PD-1 checkpoint inhibitor Keytruda™. We expect to begin human studies with our second MG1 therapy for patients with human papillomavirus (HPV) positive tumors in 2018, and have multiple other viral immunotherapies in development.

 

Program Pipeline

For more information about the MAGEA3 monotherapy trial click here and the MAGEA3 and anti-PD-1 combination trial click here.

our team

Leadership

Turnstone Biologics was founded by world-leading experts in oncolytic viruses and immunotherapies who have defined and advanced the field over the course of multiple decades. Our leadership team includes experts from academia and the life sciences industry who share the vision of bringing innovative viral immunotherapies based on our unique oncolytic Maraba virus platform to patients.

close
Sammy Farah, Ph.D., M.B.A.

Sammy Farah, Ph.D., M.B.A.

President and Chief Executive Officer

Dr. Sammy Farah has extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry. He joined Turnstone Biologics from Synthetic Genomics Vaccines, Inc., where he served as President. Prior to that, he was Chief Business Officer of Immune Design Corp. And before then, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation, and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah earned an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in biochemical engineering from Stanford University, and a B.S. in biochemical engineering from the Massachusetts Institute of Technology.

close
Mike Burgess, MBChB, Ph.D.

Mike Burgess, MBChB, Ph.D.

President of R&D

Dr. Mike Burgess brings 20 years of drug research and development experience to Turnstone Biologics. At Bristol-Myers Squibb, he led strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutic areas, including oncology. Prior to this at Roche, Mike held several different senior leadership positions, including acting global head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Before joining Roche, Mike spent 7 years at Lilly working on early stage oncology trials. Mike received his medical degree (MBChB) and a Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology.

close
Kris Elverum, M.B.A.

Kris Elverum, M.B.A.

Chief Business Officer

Kris Elverum has more than 12 years of experience in the pharmaceutical/biotech industry, with expertise in corporate strategy, business development, commercial and operations. He joined Turnstone Biologics from SQZ Biotech, a pre-clinical stage biotechnology company developing cell therapies, where he was Chief Business Officer. Prior to that, he led the U.S. commercial model for CTL019, Novartis’ breakthrough CAR-T cell therapy, and other CAR-T cell immunotherapies. Earlier in his career, he held various commercial roles for Novartis Pharmaceuticals and served as Global Head of Strategy for Sandoz. Before that, he was an Engagement Manager with McKinsey & Co. where he served clients across the healthcare value chain. Kris earned an M.B.A. and a B.S. from the University of Minnesota’s Carlson School of Management.

close
Brian Lichty, Ph.D.

Brian Lichty, Ph.D.

Senior Vice President, Basic Research

Dr. Brian Lichty is a distinguished scientist with extensive expertise in oncolytic viruses and related immunotherapies, including seminal work with Dr. John Bell at the Ottawa Regional Cancer Centre. He is a professor in the Department of Pathology & Molecular Medicine and the McMaster Immunology Research Centre (MIRC) at McMaster University. Dr. Lichty’s expertise includes influence research in the identification of strategies to leverage oncolytic viruses to harness the patient’s immune system in a sustainable manner, including vaccine design and engineering to directly engage the adaptive immune system tumor-specific and/or to enhance combinations with other immunotherapies. He is also director of the Robert E. Fitzhenry vector lab at McMaster University where clinical-grade viral vaccines are manufactured for human clinical trials. Dr. Lichty earned a Ph.D. from the University of Toronto and a B.Sc. from the University of Guelph.

close
José Manuel Otero, Ph.D.

José Manuel Otero, Ph.D.

Vice President, Manufacturing & CMC

Dr. José Manuel (Manny) Otero has 15 years of experience in the biopharmaceutical industry, including in bioprocess development, manufacturing, and CMC of vaccines and complex biologics. He joined Turnstone Biologics from Seres Therapeutics, Inc., a leader in human microbiome therapeutics, where he was Vice President of Bioprocess Development and Manufacturing. At Seres Therapeutics, Dr. Otero oversaw the expansion of the bioprocess development and manufacturing group, and was the corporate team leader for the first synthetic microbiome therapeutic to enter Phase 1b clinical studies in the United States. Prior to that, Dr. Otero was Director of Engineering at Merck & Co.’s Vaccine Manufacturing Sciences & Commercialization division. In that role, he supported development programs for the Varivax™, Zostavax™, ProQuad™, and MMRII™ franchises. Prior to that role, he was Head of Fermentation Process Development, Vaccine Process Development within Merck Research Labs. Dr. Otero has authored more than 20 peer-reviewed publications. He earned a Ph.D. in chemical and biological engineering from Chalmers University of Technology in Gothenburg, Sweden, and an M.Eng. in biomedical engineering and a B.S. in chemical engineering from the Massachusetts Institute of Technology.

close
Maura Campbell, Ph.D.

Maura Campbell, Ph.D.

Vice President, Corporate Affairs

Dr. Maura Campbell has spent more than 20 years in technology transfer and the management and commercialization of intellectual property (IP). She has business management experience in all key sectors of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations (National Centre of Excellence [NCE]). Maura joined Turnstone Biologics from VBI Vaccines where she served as Director, Intellectual Property. She also was with the Ottawa Hospital Research Institute (OHRI) as a Senior Research Program Manager, where she oversaw the oncolytic vaccine project commercialization. Earlier in her career, Maura was the Director of Intellectual Property for PainCeptor Pharma Corporation, the Manager of Technology Transfer & Commercialization for the OHRI, and the Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems at NCE. She has served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs. Maura received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston.

close
Caroline Breitbach, Ph.D.

Caroline Breitbach, Ph.D.

Vice President, Translational Development

Dr. Caroline Breitbach joined Turnstone Biologics from SillaJen Biotherapeutics (formerly Jennerex) where she was Vice President, Clinical and Translational Research. In that position, she oversaw translational and early-stage clinical development of an oncolytic immunotherapy and contributed to lead candidate development from Phase 1 through initiation of Phase 3 evaluation. Previously, she worked in Dr. John Bell’s group at the University of Ottawa, where she evaluated acute effects of oncolytic viruses on the tumor immune microenvironment. She earned a Ph.D. in biochemistry from the University of Ottawa and an Honor’s B.Sc. in microbiology and immunology from McGill University.

close
John Bell, Ph.D.

John Bell, Ph.D.

Ottawa Hospital Research Institute

Dr. John Bell began his independent research career at McGill University before moving to the University of Ottawa and becoming a professor in the Department of Medicine. He is a member of the Center for Innovative Cancer Therapeutics at The Ottawa Hospital Cancer Center and a Senior Scientist at the Ottawa Hospital Research Institute. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox-funded group from across Canada that is developing virus-based cancer therapeutics, and is the Director of the Biotherapeutics Program at the Ontario Institute for Cancer Research. John is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a Fellow of the Royal Society of Canada. Dr. Bell received a Ph.D. from McMaster University and then trained at the Medical Research Council in London, U.K.

close
Brian Lichty, Ph.D.

Brian Lichty, Ph.D.

McMaster University

Dr. Brian Lichty is a distinguished scientist with extensive expertise in oncolytic viruses and related immunotherapies, including seminal work with Dr. John Bell at the Ottawa Regional Cancer Centre. He is a professor in the Department of Pathology & Molecular Medicine and the McMaster Immunology Research Centre (MIRC) at McMaster University. Dr. Lichty’s expertise includes influence research in the identification of strategies to leverage oncolytic viruses to harness the patient’s immune system in a sustainable manner, including vaccine design and engineering to directly engage the adaptive immune system tumor-specific and/or to enhance combinations with other immunotherapies. He is also director of the Robert E. Fitzhenry vector lab at McMaster University where clinical-grade viral vaccines are manufactured for human clinical trials. Dr. Lichty earned a Ph.D. from the University of Toronto and a B.Sc. from the University of Guelph.

close
David Stojdl, Ph.D.

David Stojdl, Ph.D.

University of Ottawa

Dr. David Stojdl pioneered the exploration of host-virus interactions critical to oncolytic therapy to guide the clinical development of more effective virus platforms. At the Ottawa Regional Cancer Centre, he first identified VSV as an oncolytic virus and defined the archetypal role of interferon signaling in tumor-specific oncolytic virus targeting. Since joining the CHEO Research Institute in 2004, Dr. Stojdl has discovered and developed several novel oncolytic vector platforms, including the Maraba oncolytic virus platform. Dr. Stojdl also directs the CHEO Automated Screening Centre (CASC), leveraging state-of-the-art high-throughput robotic screening technology to uncover new insights for the clinical development of oncolytic virus biotherapies. Dr. Stojdl is a professor in the Department of Pediatrics and Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He was a scientific co-founder and consultant to Jennerex Biotherapeutics (later acquired by SillaJen Biotherapeutics). He received a Ph.D. from the University of Ottawa and an M.S. and B.S. in microbiology and immunology from the University of Western Ontario.

close
Brad Bolzon, Ph.D.

Brad Bolzon, Ph.D.


Dr. Brad Bolzon is a Managing Director at Versant Ventures and on the biotech investment team. He has more than 13 years of global pharmaceutical industry experience. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances for F. Hoffmann-La Roche. Under his leadership, Roche established alliances with more than 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.

close
Jerel Davis, Ph.D.

Jerel Davis, Ph.D.


Dr. Jerel Davis is a Managing Director at Versant Ventures and is based in Vancouver. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups. He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised pharmaceutical, biotechnology, medical device and molecular diagnostics companies. He has worked in a number of healthcare markets globally including the United States, Europe, China, Russia and India. Jerel was a post-doctoral researcher at Stanford University and worked in research at Amgen.

close
Rishi Gupta, J.D.

Rishi Gupta, J.D.


Rishi Gupta is a private equity partner at OrbiMed. Prior to that, he was a healthcare investment banker at Raymond James & Associates, served as manager of corporate development at Veritas Medicine and was a summer associate at Wachtell, Lipton, Rosen & Katz. Rishi has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world. In addition to Turnstone Biologics, he serves or has served on the boards of Dimension Therapeutics, Symbiomix Therapeutics, Avitide, Verona Pharma, ChemoCentryx and Sientra. He has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae and ORIC Pharmaceuticals. Rishi earned a J.D. from the Yale Law School and an A.B. degree magna cum laude in biochemical sciences from Harvard College.

close
Ben Auspitz

Ben Auspitz


Ben Auspitz is a Partner at F-Prime Capital and has worked in the pharmaceutical and life science industry for more than 20 years, both as a consultant and investor. Before joining F-Prime Capital, he served as Therapeutic Area Head for immuno-inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In that role, he oversaw the advancement of seven programs from assay stage into Phase 2 clinical studies, and was co-inventor on 15 product patents. Ben focuses on therapeutics and has a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and two companies for which he was a company founder, Orchard Therapeutics and Dimension Therapeutics. He currently serves on the board of directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Symbiomix Pharmaceuticals and Compass Therapeutics. Previously, Ben was involved in F-Prime Capital investments in Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Dimension Therapeutics (NASDAQ:DMTX), and Ultragenyx (NASDAQ: RARE). He received a B.A. from Harvard University.

close
David O’Neill, Ph.D.

David O’Neill, Ph.D.


David O’Neill brings extensive experience in Pharma and biotech to his role as Acting President of FACIT.  FACIT is the commercialization partner of the Ontario Institute for Cancer Research and an active seed stage investor.  Dr. O’Neill has a wealth of networks and transaction experience through various business development roles at AstraZeneca, Ambit Biosciences (Daiichi Sankyo), Kinomescan (Discoverx/Eurofins), Fluorinov Pharma (Trillium Therapeutics).  He also held operational roles including non-clinical safety, IND submission and Project Leader during clinical development of Quizartinib.  He has provided interim executive management to FACIT spin outs Turnstone, Propellon and Novera Therapeutics. In addition to serving on the Board of Turnstone, he is also a Board Observer for Fusion Pharmaceuticals.  Dr. O’Neill holds a Ph.D from Western University from the Faculty of Health Sciences with an emphasis on heat shock protein biology.

close
Sammy Farah, Ph.D. M.B.A.

Sammy Farah, Ph.D. M.B.A.


Dr. Sammy Farah has extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry. He joined Turnstone Biologics from Synthetic Genomics Vaccines, Inc., where he served as President. Prior to that, he was Chief Business Officer of Immune Design Corp. And before then, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation, and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah earned an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in biochemical engineering from Stanford University, and a B.S. in biochemical engineering from the Massachusetts Institute of Technology.

close
John Bell, Ph.D.

John Bell, Ph.D.


Dr. John Bell began his independent research career at McGill University before moving to the University of Ottawa and becoming a professor in the Department of Medicine. He is a member of the Center for Innovative Cancer Therapeutics at The Ottawa Hospital Cancer Center and a Senior Scientist at the Ottawa Hospital Research Institute. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox-funded group from across Canada that is developing virus-based cancer therapeutics, and is the Director of the Biotherapeutics Program at the Ontario Institute for Cancer Research. John is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a Fellow of the Royal Society of Canada. Dr. Bell received a Ph.D. from McMaster University and then trained at the Medical Research Council in London, U.K.

close
Jeff Courtney

Jeff Courtney

In Memoriam

Jeff Courtney helped to form Turnstone Biologics and was an outstanding leader for FACIT (Fight Against Cancer Innovation Trust). Jeff’s life’s work and warm personality inspires all of us at Turnstone Biologics to drive forward our mission to help cancer patients, and we greatly miss his presence, leadership and friendship.

We are backed by top-tier investors who are committed to the company’s growth. We have raised approximately $50 million in venture capital financing since our inception.

Turnstone Biologics views strategic partnerships as a core component of our strategy and is interested in collaborating with biopharma companies, academic centers, and universities to transform patient care.

In the fall of 2017, Turnstone Biologics entered into a strategic research, option and license agreement with AbbVie for our Ad-MG1-MAGEA3 therapy and two research-stage candidates that are presently in development.

Careers

Turnstone Biologics’ team works with a sense of urgency to fulfill our mission. Our decision-making is driven by science and our therapeutics are designed with the patient in mind.

We value transparency, innovation, integrity and purpose as we collaborate to transform cancer care. If you’re a passionate person, and our mission and science excite you, Turnstone Biologics might be for you.

Team Member Openings

Turnstone Biologics is dedicated to excellence and innovation in every aspect of our science and business. We are actively looking for exceptional individuals who share our passion for developing and delivering next-generation viral immunotherapies. We offer competitive compensation and benefits and are an equal opportunity employer.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency.  Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

The Sr. Manager/Associate Director, Regulatory Affairs position is located in New York City and reports to the Senior Director, Regulatory Affairs.  The successful candidate will work directly with the Head of Regulatory Affairs to develop and implement innovative global regulatory strategies for novel early-stage oncolytic virus immunotherapies. S/he will lead and coordinate the preparation of Regulatory documents across cross-functional teams (Nonclinical, CMC, Clinical) and file submissions to Health Authorities according to current regulatory requirements and applicable timelines.

Responsibilities:

  • Serve as a Regulatory Lead on cross-functional program teams for products in Turnstone’s pipeline, providing strategic regulatory advice as required on all aspects of Regulatory during all stages of development
  • Responsible for planning and coordinating regulatory submissions necessary to support global clinical trials, with a view towards global product registration
  • Ensure global regulatory compliance with current applicable regulatory legislation and guidelines
  • Serve as a liaison to global Health Authorities, as applicable
  • Compile, edit, review, and submit INDs, CTAs, MAAs, and BLAs in eCTD-compliant regulatory submission format
  • Provide strategy for and compile additional applications such as Orphan, Fast Track, Breakthrough Therapy, annual reports/DSUR
  • Proactively communicate with internal stakeholders to lead and ensure regulatory strategy is understood, aligned with Program milestones and implemented by cross functional teams
  • Keep apprised of regulatory intelligence developments and communicate actionable feedback to functional teams
  • Proactively manage vendors e.g., local regulatory consultants and eCTD publisher

Experience & Qualifications:

  • BSc Required, MS/PhD preferred
  • Masters Regulatory Affairs/RAC is an asset
  • Previous experience with oncology and complex biologics preferred
  • Experience with CDRH and companion diagnostics preferred
  • Experience leading, preparing and conducting regulatory agency meetings
  • Knowledge of FDA, EMA, Health Canada, and other relevant regulatory bodies and related agencies
  • Ability to think strategically and creatively to proactively identify regulatory issues across all stages of the development process
  • Ability to work independently or as part of a team, especially with employees in other locations
  • Comfortable managing multiple projects and ability to adapt to changing priorities
  • Highly effective written and verbal communication skills and computer skills

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title SENIOR MANAGER – REGULATORY AFFAIRS.

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

 

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency.  Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

The Animal Research Technician is located in Hamilton and will bring hands-on experience with mouse husbandry and procedures such as syngenic murine tumour models, intravenous and intramuscular injections, blood collection and necropsy, including experience with processing blood and tissues for ex vivo analysis. The incumbent will conduct laboratory activities including performing experiments, analyzing data, and will work closely with other lab members.

Responsibilities:

  • Application of preclinical models to enable the translation of cancer therapies
  • Characterizing in vivo models, ex vivo assays, syngeneic tumour models, mouse models to optimize their application in preclinical and translational studies for targeted therapies, cancer immunotherapies and combination therapies
  • Be highly involved in mouse animal handling requiring subcutaneous, intraperitoneal and intravenous injections, frequent tumor measurements, and regular health monitoring of animals
  • Performs blood collection through multiple routes, gaseous anaesthesia, tissue harvesting, and animal necropsies
  • Be involved in work with culture and/or cell separation methods; virus preparation; drug preparation
  • Provide technical support for assays: viral titration, flow cytometry, and fluorescence microscopy
  • Operate lab equipment such as centrifuges, pH meters, analytical balances, spectrophotometers, light microscopes and other equipment as instructed
  • Performs simple or moderately complex technical procedures
  • Participates in data entry and data analysis, including application of statistical analysis techniques using standard software
  • May perform study-related administrative tasks. Compiles data from related and/or unrelated sources
  • Communicates findings to other lab members and maintains records of experimental data
  • Must have strong interpersonal skills
  • Must have excellent verbal and written communication skills
  • Respond to and complete tasks as instructed by the P.I. and staff associated with designated research projects by carrying out the requested activities
  • Must have a willingness to perform repetitive tasks
  • Action oriented and eager to take on new opportunities and tough challenges with a sense of urgency, high energy, and enthusiasm
  • Ability to work and contribute in a fast-paced, collaborative team environment

Experience & Qualifications:

  • BSc in related science; or Medical Laboratory Technology certification; or an equivalent combination of education and experience.
  • 2-5 years’ experience working in research in either an academic or biotech/pharma setting with strong mouse-handling skills
  • Working knowledge of CCAC guidelines, OMAFRA regulations and animal use protocols (AUPs)
  • Knowledge and familiarity with regulations, standards, and guidelines for care and use of vertebrate animals in teaching, research, and service
  • All work must be performed at the highest quality and with the highest regard for animal welfare.
  • Must have attention to detail and excellent record keeping skills
  • Must possess an excellent work ethic, maintain a professional attitude and maintain high standards to detail, being able to work independently and in a team environment with the ability to interact positively with other team members
  • Must be able to detect, analyze and resolve issues professionally as they arise

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title ANIMAL RESEARCH TECHNICIAN (Hamilton).

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency.  Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:

The position is located in Ottawa and reporting to the SVP, Discovery.  The position of Scientist/Immunologist is to manage all aspects of the discovery, validation and preclinical development to advance a novel neoantigen immunotherapy from the discovery phase into the clinic.  The incumbent will demonstrate their ability to participate in a highly matrixed and innovative research environment with a track record of translating basic research findings into novel therapeutic strategies that support clinical drug development.  They will contribute to the technical development and testing of a first-in-class personalized immunotherapy, meshing tumour genomics with individualized vaccine construction.  The position contributes both intellectually and experimentally as part of a multidisciplinary team with the development of strong cross-functional relationships being important for success.

Responsibilities:

  • Conduct research and design experiments that focus work in tumor and immune cell target identification/validation leading to innovative next generation biologics and modalities.
  • Utilize expertise to independently design, execute and analyze experiments using cellular and molecular immunological assays to investigate and uncover novel target biology and technologies to foster neoantigen targeted immunotherapy.
  • Effectively collaborate with other members of the company, including external collaborators and partners.
  • Prepare and present hypotheses, on-going progress reports, technical reports and future plans (including contributing to budget strategic presentations).
  • Supervise students and/or laboratory and research technicians in equipment management (e.g., flow cytometer) and ethical treatment of animals in research.
  • Contribute to building a culture that embraces scientific excellence, integrity, urgency, partnerships with key stakeholders and continuous learning/improvements.

Experience & Qualifications:

  • Must hold a Ph.D. in biology/immunology/oncology/pharmacology or a related field with 5+ years of experience or an acceptable combination of education and experience.
  • Robust understanding of innate and adaptive immune systems is required.
  • Experience with in vivo models, isolation and culture of primary cells (both mouse and human).
  • National Institutional Animal User Training Certification (NIAUT) an asset.
  • A working knowledge of immune based in vitro assays, flow cytometry and common molecular techniques.
  • Experience in T cell function/differentiation/signaling/regulation, phenotypic analysis of inhibitory and costimulatory targets and pathways and/or neoantigen biology and vaccines is highly preferred.

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title SCIENTIST-IMMUNOLOGIST. Although not required, you are invited to include your salary expectations in your cover letter.

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing clinical team that embraces being a learning organization with a sense of urgency, where clinical is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

The company has multiple programs either in the clinic or in late stage preclinical development. Establishing high quality scientific and development capabilities is essential for the success of the company. This position reports to the President of R&D:

Key responsibilities include:

Clinical Development:

  • Responsible for clinical development strategies including phase 1 through 3, life cycle managements, medical affairs and safety reporting.
  • Oversees and participates in all interactions with regulatory agencies related to his/her clinical programs.
  • Leads and oversees the tactical development of clinical trial programs, including protocol writing, interpretation of clinical data, and literature reviews.
  • Ensures the highest quality of ethical standards and scientific methods are applied to clinical and scientific programs.
  • Ensures that clinical timelines and budgets are met and provides solutions for potential challenges to mitigate any impact on such timelines or budgets.
  • Ensures the identification, recruitment and selection of appropriate clinical investigators.
  • Partner with the supporting functions, project leadership and management, clinical operations, regulatory and biomarkers to ensure optimally integrated development
  • Partner with the Scientific Founders to provide clinical insights to better identify appropriate clinical candidates
  • Define the patient selection strategy, if required, for the assets and partners with the bioassay lead to identify the appropriate research or companion diagnostic tests.
  • Partner with internal and external thought leaders to identify trends in oncology and define efficient approaches to ensure preclinical discoveries are able to address unmet medical through cutting edge clinical development
  • As part of the R&D leadership group provide scientific, clinical and operational input to the overall R&D strategy and organization

Corporate Leadership;

  • Assist in creating a strong and dynamic scientific and medical culture consistent with the position of Turnstone Biologics as the world’s leading viral immunotherapy company
  • Present to the Board and/or Scientific Advisory Board and/or to external investor groups as required.
  • Enhance the external presence of the company through presentations at scientific meetings, to academic cooperative groups and to the investigator community.
  • Support business development and provide clinical and scientific expertise to external partnerships.

Key requirements include:

  • A MD/PhD with a strong background in immuno-oncology and a track record of leading academic and clinical research
  • Excellent scientific rigor and experience in overseeing multiple programs in oncology and hematology
  • Proven pharmaceutical experience working with both preclinical research and clinical development
  • An ability to work in a small scientifically driven biotech company in which resources may be limited and hence a willingness to work beyond job title and scope to ensure the success of the programs and company.
  • Strong external presence with key opinion leaders within the immuno-oncology world
  • A track record of success in delivering on goals with academic and industrial partners. Demonstrated success at recruiting and retaining highly qualified talent

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title VP – CLINICAL DEVELOPMENT.

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing CMC team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

What’s in it for you?

In this role, you will have the opportunity to design, build, implement, and operate a clinical manufacturing supply chain for our suite of novel biotherapeutics to combat cancer. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic. Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you. One that leverages your expertise, while challenging you to develop new skills. This role will include driving a raw materials inventory, product inventory, distribution, and warehousing, all while serving as the primary contact amongst our network of external products to move product from R&D to GMP manufacturing to the patients we serve. Fortunately, the Turnstone CMC team has already initiated two clinical studies with Health Canada, so you’re not starting from zero, but we need someone to really own, drive, and lead our supply chain, showing us how the professionals do it, all while remaining flexible, dynamic, working with a sense of urgency, and innovation. This is definitely a ‘roll up your sleeves’ role, but we’re hiring a leader that is setting the foundation for mature, manufacturing supply chain capable of supporting late-stage (Ph3/Pivotal) clinical studies, and commercial launch – you will bring the vision.

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Wednesday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

If you are interested in leading critical procurement, warehousing, and logistics operations under highly fluid, rapidly changing conditions – this job is for you! You’ll enjoy a diverse role as you partner closely with various groups such as Manufacturing Sciences & Technology, Analytical Development and Quality Control, Manufacturing Operations, Quality Assurance, and Clinical Operations to ensure all types of materials are procured, appropriately distributed, and stored in a compliant manner. In addition, you’ll partner closely with CDMOs, CROs, and CTOs to manage relationships, negotiate pricing and terms, and conquer challenges.  You’ll use your well-developed communication skills in monitoring and enforcing requirements with all vendors and as you work with internal stakeholders at all levels.  You’ll have experience working with some or all of the following, as they relate to supply chain management:

  • Inventory and Enterprise Resource Management systems
  • Procurement systems
  • Critical logistics, including import/export, cold chain, and time-sensitive shipping
  • External vendors, including critical material suppliers and contract development/manufacturing organizations (CDMOs), contract testing organizations (CTOs), and contract research organizations (CROs)
  • Warehouse materials management, including receipt, storage, issuance, and shipping, preferably at multiple sites
  • Quality systems (change control, deviations, corrective and preventive actions, document control)
  • Experience with Lean principles, Kanban, Just-In-Time logistics, Continuous Improvement, etc. are a plus. This is definitely a ‘hands-on’ role with incredible upside opportunities.

The details

This role is best suited for supply chain professionals with significant experience developing and managing a GMP clinical manufacturing supply chain. You’ve likely studied supply chain and logistics, or perhaps were a classically trained scientist/engineer and supplemented your education to be successful. You must be able to demonstate both leadership and a willingness to be a ‘do-er’, likely having 5 years or more experience in GMP manufacturing supply chain and logistics. You have demonstrated the ability to manage both small and large projects, multi-tasking effectively, and having an external presence that is professional, collaborative, and influential. You will need to travel monthly to our various vendors, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Vice President of CMC/Manufacturing at Turnstone and be a part of the CMC Leadership Team. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title MANUFACTURING SUPPLY CHAIN LEADER.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing CMC team that embraces being a learning organization with a sense of urgency, where CMC is a differentiator and enabler rather than a cost-center. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com or email info@turnstonebio.com.

What’s in it for you?

In this role, you will have the opportunity to lead, drive, and own GMP clinical manufacturing operations for a suite of novel biotherapeutics to combat cancer. On the heels of a successful Series B financing, Turnstone’s CMC team is expanding to support the development of several parallel candidates towards the clinic. Joining Turnstone at this early phase, will allow you to actively participate in developing a role designed just for you: one that leverages your expertise, while challenging you to develop new skills. This role will include partnering very closely with our Manufacturing Sciences & Technology group to understand the Drug Substance and Drug Product processes, with a collaborative effort to successfully transfer those processes to our network of CDMOs. Once transferred, you will lead all manufacturing operations including batch production record management, manufacturing schedule, providing ‘on-the-floor’ review and support as required, and overcoming challenges related to manufacturing deviations. You are truly the relationship manager and interface between Turnstone Biologics and our Manufacturing partners, representing us with the professionalism, creativity, and collaborative spirit that embodies who we are. Fortunately, the Turnstone CMC team has already initiated two clinical studies with Health Canada, so you’re not starting from zero, but we need someone to really own, drive, and lead our manufacturing operations, showing us how the professionals do it, all while remaining flexible, dynamic, working with a sense of urgency, and innovation. This is definitely a ‘roll up your sleeves’ role, but we’re hiring a leader that is setting the foundation for mature, manufacturing operations capable of supporting late-stage (Ph3/Pivotal) clinical studies, and commercial launch – you will bring the vision.

How do you know if you’re the right fit?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Wednesday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you. If you are interested in leading, driving, and owning manufacturing operations for an early clinical-stage company, where you need to both provide vision and strategy while rolling up your sleeves, then this role may be for you! You’ll enjoy a diverse role as you partner closely with various groups such as Manufacturing Sciences & Technology, Analytical Development and Quality Control, Supply Chain, Quality Assurance, and Clinical Operations. You will have led GMP manufacturing operations for complex biopharmaceuticals, ideally live-virus vaccines or similar, and will have both clinical and commercial manufacturing experience. You’ll use your well-developed communication skills and ability to influence and partner very closely with our networks of CDMOs and internal stakeholders at all levels.  You’ll have experience working with some or all the following, as they relate to manufacturing operations:

  • Live-virus manufacturing experience, ideally hands-on as well as leading broader manufacturing teams or projects partners with external vendors
  • Very well versed in GMPs with a clear understading of ‘phase-appropriateness’ as well as an appreciation for continuous improvement
  • A relationship manager and primary interface for external vendors, including critical material suppliers and contract development/manufacturing organizations (CDMOs), contract testing organizations (CTOs), and contract research organizations (CROs)
  • Quality systems (change control, deviations, corrective and preventive actions, document control)
  • Experience with Lean principles, Kanban, Continuous Improvement, etc. are a plus. This is definitely a ‘hands-on’ role with incredible upside opportunities.

The details

This role is best suited for manufacturing professionals with significant experience developing and managing a GMP manufacturing operation. You’re likely a classically trained scientist/engineer and supplemented your education to be successful, particularly with training in operational excellence and manufacturing. You must be able to demonstate both leadership and a willingness to be a ‘do-er’, likely having 5 years or more experience in GMP clinical or commercial manufacturing. You have demonstrated the ability to manage both small and large projects, multi-tasking effectively, and having an external presence that is professional, collaborative, and influential. You will need to travel monthly to our various vendors, and also visit our Ottawa and NYC offices often to stay connected, productive, and excited. This role will report to the Vice President of CMC/Manufacturing at Turnstone and be a part of the CMC Leadership Team. Based on a mutual discussion of fit, the successful candidate(s) will reside at either the Ottawa or New York office location.

To Apply:

Please forward applications via email only to hr@turnstonebio.com including a cover letter and resume. In the e-mail subject line, please indicate the position title MANUFACTURING OPERATIONS LEADER.


Turnstone Biologics welcomes and encourages applications from people with disabilities.
Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Notice to Recruiters: Turnstone Biologics values our recruiting partnerships, but to protect the interest of all parties, we do not accept unsolicited resumes from recruiters. All recruiting is managed through our human resources department.

Contact

Ottawa

787 Bank Street, 2nd Floor
Ottawa, Ontario K1S 3V5
(613) 421-8930

New York City

110 East 25th Street
New York, New York 10010
(613) 421-8930

General

Please contact us with any questions
or comments.

Info@turnstonebio.com

Media

Please contact Pure Communications
for any media inquiries.

Turnstone@W2OGroup.com